Jay A. Berzofsky, M.D., Ph.D.
Dr. Berzofsky pioneered characterization of B- and T-cell epitopes and their modification to make epitope-enhanced vaccines, discovered the importance of T cell avidity in viral/tumor clearance, pioneered use of defined molecular adjuvants to alter quality of immune responses, advanced mucosal HIV vaccines, discovered NKT cell regulation of tumor immunity, and blocked negative regulation by TGF-beta, IL-13, and regulatory cells to enhance tumor immunity and vaccine efficacy. He translated these strategies to clinical trials in prostate cancer, melanoma, and HER2-positive cancers. As chief, he oversees the Vaccine Branch’s basic, translational, and clinical research in cancer and retroviral vaccines and immunotherapy.
Center for Cancer Research
National Cancer Institute
Building 41, Room D702D
Bethesda, MD 20892-5062
T Lymphocyte Recognition of Antigens and Applications to Vaccines for AIDS and Cancer
Our research focuses on elucidating new fundamental principles governing T cell activation, regulation, and effector function, and employing these to develop more effective vaccine and immunotherapy strategies for HIV, cancer, and viruses causing cancer.
This involves several steps that together comprise a push-pull approach. First, we optimize the antigen to improve immunogenicity by epitope enhancement, changing the amino acid sequence to increase affinity for the relevant major histocompatibility (MHC) molecule. We have done this for several cancer antigens, including the prostate cancer antigen, TARP, and have now completed a phase I/II clinical trial in Stage D0 prostate cancer patients with rising PSA levels to determine whether the TARP peptide vaccine can reduce the rate of PSA rise. The slope of PSA rise was significantly reduced in 72-74% of patients at 24 and 48 weeks, respectively. A randomized controlled phase II trial is just opened.
The second step is to push the response with molecular adjuvants, such as cytokines and Toll-like receptor (TLR) ligands, to improve not only the quantity but also the quality of the response. We published that IL-15 is an important mediator of CD4 T cell help for CD8 T cells, in that it is sufficient to substitute for help in animals depleted of CD4 T cells, to allow a memory CD8 response and prevent TRAIL-mediated apoptosis, and also it is necessary for help. If dendritic cells (DCs) cannot be induced by helper cells to make IL-15, then the help is not adequately delivered to CD8 T cells. We also found that IL-15 increased the avidity of the CD8 T cells, necessary for effective clearance of virus or tumor cells. We extended this research to human CD8 T cells and showed that a primary in vitro CD8 T cell response was dependent on CD4 help but that IL-15 could be substituted, but not IL-2. IL-15 also restored the in vitro responses of CD8 T cells from HIV-infected individuals. We also found that IL-15 affects DC and CD4+ T cell subpopulations in the gut mucosa.
We also investigated TLR ligands as adjuvants, because these can mature DCs and induce their production of cytokines like IL-12 and IL-15. We published a study showing synergy between pairs of TLR ligands that work through different intracellular signal transducers, MyD88 or TRIF, and determined the mechanism in DCs involving unidirectional cross-talk from TRIF to enhance MyD88-dependent cytokine production. We have now found a triple TLR ligand combination that induces more effective protection against virus infection. This combination does not increase T cell quantity, but improves quality by inducing higher avidity T cells, and induces more IL-15 production, accounting for the higher avidity. We tested the triple TLR ligands, IL-15, both or neither as vaccine adjuvants in a peptide-prime, MVA-boost mucosal vaccine for SIV in macaques, challenging intrarectally with SIVmac251. Only the macaques receiving both types of adjuvants showed some protection, so we investigated correlates of protection. In the adaptive immune arm, surprisingly only polyfunctional CD8 T cells specific for SIV antigens, but not total specific T cells measured by peptide-MHC tetramer binding, correlated with protection. In the innate immune arm, we found the adjuvants induced long-lived innate protection induced by the adjuvant combination. Thus, vaccine strategies that induce both innate and adaptive immunity may be the most efficacious.
The third step is to target the immune response to the relevant tissue, the mucosa in the case of HIV. We have studied mucosal T cell trafficking and discovered a lack of equilibrium between the intraepithelial compartment and the lamina propria in the small intestine, leading to a distinct founder effect in the narrower repertoire of intraepithelial T cells. We have previously compared mucosal versus subcutaneous delivery of a peptide AIDS vaccine in macaques and found that only the mucosal route induced CD8 T cells in the gut mucosa and was more effective at reducing virus load even in the blood because it more effectively cleared virus from the major reservoir for SIV replication in the gut mucosa that was seeding the bloodstream. We further found that induction of such CD8 T cells in the gut mucosa before intrarectal challenge with an AIDS virus could significantly delay dissemination of virus from the initial site of infection in the mucosa to the bloodstream. We conclude that the local CD8 T cell response was able to reduce the initial nidus of infection at the site of transmission, and that if we could more completely eradicate the virus at the initial nidus of infection, we might nip it in the bud and abort the infection before it disseminated and became established. We showed that this protective effect was correlated with induction of high avidity CD8 T cells in the gut mucosa, and not with CD8 T cells in the blood or peripheral lymph nodes. We also just published a new paradigm for induction of CD8 T cell immunity directly in vaginal mucosa (a type II mucosa that lacks organized lymphoid structures), independent of draining lymph nodes or other lymphoid structures, overturning textbook dogma.
Development of a mucosal vaccine for HIV is most important because 85-90% of transmission is through a mucosal route, either genital or gastrointestinal, and because the major site of replication is in the gut mucosa, regardless of the route of transmission. We then devised a nanoparticle vaccine coated in a way to allow release in either the small or large intestine after oral delivery. Delivery to the large intestine mimicked intrarectal immunization by a more practical route, and achieved protective T and B cell immunity against both rectal and vaginal viral challenge, whereas delivery to the small intestine did not.
We have translated these findings to non-human primate studies where we have preliminary evidence of activity in two independent macaque vaccine studies, as the preclinical basis for a human clinical trial. In the process, we discovered that the small and large intestinal mucosae are separate subcompartments in which we can selectively induce a response by targeting the antigen for release in one or the other. This implies different homing receptors for T cells to each compartment. We found that colonic DCs program T cells to preferentially return to the colon, in contrast to small intestinal DCs that induce homing to the small intestine, attributable to different levels of retinoic acid and induction of different chemokine receptors. We also found that colonic DCs can patrol the gut lumen near colon patches under chemokine control and bring antigen back to the lamina propria.
The fourth step is to pull the response by removing the brakes, i.e., blocking the negative regulatory mechanisms that inhibit the immune response. We previously discovered a new immunoregulatory pathway involving NKT cells that suppresses tumor immunity. The NKT cells make IL-13 that induces myeloid cells to make TGF-β, which suppresses the CD8 T cell response. However, as we and others have also seen that NKT cells can protect against tumors, we needed to resolve this paradox. We found that type I NKT cells (using an invariant TCRα chain) protected, whereas type II NKT cells (using diverse T cell receptors) suppressed immunity. Moreover, selective activation of type I or type II NKT cells showed they cross-regulated each other, defining a new immunoregulatory axis, analogous to the axis between Th1 and Th2 cells that has profoundly affected immunology. The NKT cells are among the first responders, so the balance along the NKT axis could influence subsequent adaptive immune responses. We found that type II NKT cells also suppress conventional CD4 and CD8 antigen-specific T cells, so they are broadly suppressive. We are examining the mechanisms of suppression and also investigating the relationship between suppressive NKT cells and CD25+ Foxp3+ T regulatory cells.
In one tumor model we find that both Treg cells and type II NKT cells can suppress tumor immunity, but that the effect of the latter is counterbalanced by type I NKT cells so this third T cell regulates the balance between the regulators. In trying to tip the balance along the NKT regulatory axis, we find that blocking IL-13 can delay growth of spontaneous, autochthonous tumors even in HER-2 transgenic mice that develop aggressive independent tumors in all 10 mammary glands. Conversely, stimulating with a type I NKT cell agonist can protect against tumors.
We discovered a new class of NKT cell agonist represented by beta-mannosylceramide, that protects against tumors by a novel mechanism dependent on TNF and nitric oxide synthase (NOS) but not on interferon-gamma, distinct from that of alpha-galactosylceramide which is dependent on interferon-gamma and not on TNF or NOS. We are exploring the mechanism of this protection, but because this new agonist avoids natural alpha-gal antibodies and induces less anergy than alpha-GalCer, and because it synergizes with alpha-GalCer and also stimulates human iNKT cells, we are pursuing it as an immunomodulator to improve immunity against human cancer. We are comparing different NKT agonists, so that we may be able to tailor the protective response to fit different conditions and to achieve synergy between different mechanisms of protection. A key mediator of the NKT regulatory pathway and an important regulator of T regulatory cells is TGF-β. We have found that blockade of TGF-β can protect against certain tumors in mice, and can synergize with anti-cancer vaccines in two mouse models. The protection is dependent on CD8 T cells, and when used in combination with a vaccine, the anti-TGF-β increases the number of both total and high avidity CD8 T cells. We have translated this into a human clinical trial of a human anti-TGF-β monoclonal antibody in a CRADA with Genzyme, in melanoma and renal cell cancer. The phase I study showed some activity including one 89% partial remission and several cases of mixed responses or stable disease. We would like to combine the antibody with a vaccine to induce anti-cancer immunity.
Another important mediator of negative regulation is the myeloid-derived suppressor cell (MDSC). This population is known to increase in cancer and HIV infection. We have now found that it can also be increased by vaccines, and can thus reduce the efficacy of the vaccine. We found that rhesus macaques given an AIDS vaccine intrarectally had more MDSCs than animals given the same adjuvants without the vaccine, and that protection was diminished by the presence of the MDSCs. T cell activity was increased by depletion of MDSC, and the MDSCs were shown to suppress when added into T cell cultures. Thus, vaccine design must take into account ways to prevent this vaccine-induction of MDSCs.
Finally, we published that an adenovirus vaccine expressing the extracellular and transmembrane domains of HER-2 can cure large established mammary cancers and lung metastases in mice. The mechanism surprisingly involves antibodies that inhibit HER-2 function, rather than T cells. We have now made a similar recombinant adenovirus expressing the human HER-2 domains and have opened a clinical trial in human cancer patients that is accruing patients first who are naive to trastuzumab and if safe in that setting, patients who have failed trastuzumab. We already have preliminary data of clinical activity in several patients with advanced metastatic cancer.
Selected Key Publications
An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes.Proc. Natl. Acad. Sci. U.S.A. 85: 3105-9, 1988. [ Journal Article ]
Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.Proc Natl Acad Sci U S A. 93: 4102-7, 1996. [ Journal Article ]
- Nat Immunol. 1: 515-20, 2000. [ Journal Article ]
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance.J Exp Med. 202: 1627-33, 2005. [ Journal Article ]
Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection.Nat. Med. 18: 1291-6, 2012. [ Journal Article ]
Dr. Berzofsky was appointed chief of the new Vaccine Branch, Center for Cancer Research, National Cancer Institute, in 2003 after having served as chief of the Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, NIH, since 1987. He graduated Summa cum Laude from Harvard (1967), and received a Ph.D. and M.D. from Albert Einstein College of Medicine. After interning at Massachusetts General Hospital, he joined NIH in 1974. Dr. Berzofsky's research has focused on antigen processing and presentation by MHC molecules, the structure of antigenic determinants, cytokine and regulatory cell control of T cell function and avidity, and translation to the design of vaccines for AIDS, malaria, cancer, and viruses causing cancer. He has published 483 scientific works. Dr. Berzofsky has received a number of awards, including the U.S. Public Health Service Superior Service Award, the 31st Michael Heidelberger Award, the McLaughlin Visiting Professorship, the Australasian Society for Immunology Visiting Lectureship, and the Tadeusz J. Wiktor Memorial Lectureship. He is the past president of the American Society for Clinical Investigation, and a fellow of the American Association for the Advancement of Science and was elected Distinguished Alumnus of the Year for 2007 by the Albert Einstein College of Medicine. He was also elected chair of the Medical Sciences Section of the American Association for the Advancement of Science (AAAS) 2007-08. He won the NIH Director's Award and NCI Merit Award in 2008 and a Merit Award in 2011.
|Position||Number of Positions||Contact E-mail||Contact Name||Contact Phone|
|Postdoctoral Fellow||Multiple Positions Availableemail@example.com||Jay Berzofsky|
|Kurt Berckmueller||Postbaccalaureate Fellow (CRTA)|
|Anja Bloom Ph.D.||Postdoctoral Fellow (Visiting)|
|Sophia Brown||Research Biologist (Contr)|
|Katharine Clark||Postbaccalaureate Fellow|
|Lee England||Physician Assistant|
|Tianbo Jiang||Postbaccalaureate Fellow (CRTA)|
|Shweta S. Kulkarni||Postbaccalaureate Fellow|
|Laurel Lagenaur Ph.D.||Guest Researcher|
|Hoyoung Maeng, M.D.||Staff Clinician|
|Chandirasegaran Massilamany Ph.D.||Research Fellow|
|Katherine M. McKinnon||Staff Scientist|
|Asad Moten||Special Volunteer|
|Salil J. Ojha||Postbaccalaureate Fellow|
|Lise H. Pasquet Ph.D.||Postdoctoral Fellow (Visiting)|
|Charles Pendleton M.S.||Research Chemist|
|Brenda Roberson R.N.||Clinical Research Nurse|
|Shahram Solaymani-Mohammadi Ph.D.||Postdoctoral Fellow (CRTA)|
|Yongjun Sui, Ph.D.||Staff Scientist|
|Masaki Terabe Ph.D.||Associate Scientist|
|Yichuan Wang M.D., Ph.D.||Research Fellow|
|Lauren V. Wood, M.D.||Special Volunteer|
|Zheng Xia||Research Biologist|